Biotech IV Monitor

BHVN — Biohaven Ltd.

$2.2B market cap · 7 upcoming readouts tracked

Clinical trial readout dates for Biohaven Ltd., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts75 Phase 3
Market cap$2.2B
Cash & investments$161M~1 quarters at last loss rate
Recent 8-K filings3latest 2026-11-16

Upcoming readouts

Phase 2 BHV-7000
Focal Epilepsy · NCT06443463
December 2026
Enrolling
Phase 2/3 BHV-7000
Focal Epilepsy · NCT06132893
December 2026
Ongoing
Phase 2/3 BHV-8000 10mg
Parkinson Disease · NCT06976268
August 2027
Recruiting
Phase 3 BHV-1300
Graves Disease · NCT07661056
January 2028
Recruiting
Phase 1/2 BHV-1510
Solid Tumor · NCT06384807
February 2028
Recruiting
Phase 3 BHV-1400
IgA Nephropathy · NCT07642050
September 2028
Not Yet Recruiting
Phase 2/3 BHV-1300
Graves' Disease · NCT07901244
December 2028
Not Yet Recruiting

Cash position

Biohaven Ltd. reported $161M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $129M; at that rate the cash would last about 1 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Reg FD Disclosure — often a data announcement2026-11-16
8-K Results of Operations — earnings, may carry pipeline updates2026-10-29
8-K Reg FD Disclosure — often a data announcement2026-10-22

Companies working on similar indications

Discussion

No messages yet. If you follow BHVN, you can start the conversation.
Track BHVN in real time
See live implied volatility for BHVN and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on BHVN
Contact — questions or corrections about BHVN: dukeupt@gmail.com